Trendletter20 April 2021
The Trendlines Group Trendletter April 2021
“Dual listing on TASE … Vvital Biomed appoints Ed Rieflin … Sol Chip partnership” Read more >
“Dual listing on TASE … Vvital Biomed appoints Ed Rieflin … Sol Chip partnership” Read more >
Ed Rieflin brings 19 years of leadership experience from Thoratec, St. Jude Medical and Abbott Laboratories to advance Vvital’s mitral valve solution Read more >
“Annual Report FY2020 … ZygoFix investment round … Fireside chat with CEOs …” Read more >
” FY 2020 financial results … Israel Medtech Webinar … AgriVest 2021″ Read more >
” 2020 Highlights … FDA clearance for OrthoSpin … Vensica FIH results … ProArc on ExitValley … AFIC 3i Accelerator … SPRINT pre-incubation” Read more >
The second-generation system represents a technological leap forward as it is more user friendly, covers all strut range sizes, and is lighter by 20%. Read more >
Company raises $1.5 million to improve clinical outcomes of ischemic stroke patients with a next-generation aspiration catheter. Read more >
